WIN will address the most critical question facing clinical cancer research: Why the improvement of survival still remains limited for most cancer patients?
WIN 2016 will be held in Paris, France from 27-28 June 2016. It is the 8th edition of a successful series of symposia organized by the Worldwide Innovative Networking (WIN) Consortium, dedicated to advancing personalized cancer medicine through global collaboration. This year WIN has chosen to address the critical question facing cancer research: How innovative use of targeted therapies can improve survival of greater numbers of cancer patients?
Under the chairmanship of Josep Tabernero, Director, the Vall d´Hebron Institute of Oncology (VHIO), Spain, the WIN Symposium will present a unique opportunity by bringing together a forum of world-class experts from different backgrounds including patient advocacies, academic and private research institutes and industry to address contemporary challenges and controversies around the next innovative steps in cancer therapy that will significantly improve patients’ outcomes.
“By engaging all stakeholders in oncology – a contributing factor that makes the WIN symposia so great, we will collectively seek to establish ways in which we can help the policy makers and regulatory bodies to achieve greater cross-border harmonization to ensure that cancer remains a forerunner in advancing and implementing precision medicine,” comments Josep Tabernero.
“As Symposium Chair, I can promise all participants ´first-outing´ novel data and discovery in state of the art personalized cancer therapy trials, with unparalleled opportunity to interact with world class leaders who are trailblazing precision oncology across borders,” he continues.
Themes that will be addressed:
• Patients’ and advocacy perspectives
• New tools for early diagnosis, selecting therapies and monitoring
• Innovative clinical trials to substantially improve outcome
• Relevant models and critical preclinical data before moving to the clinic
• Translation of big data into clinical opportunities
“The annual symposium is the most visible part of the WIN Consortium’s activities, but perhaps the most exciting part of WIN is the engagement of all the different parties, from academic institutions to industry collaborators, and the unique opportunity this offers to truly collaborate in developing the next generation of clinical trials,” says John Mendelsohn, Chairman WIN Consortium, Director Khalifa Institute for Personalized Cancer Therapy, Past President, UT MDAnderson Cancer Center, USA.
WIN2016 Key dates
April 1, 2016 Early bird registration deadline
May 16, 2016 Abstract submission deadline
June 27-28, 2016 WIN 2016 Symposium
WIN 2016 will be happening around the UEFA European Football Championship (UEFA EURO 2016) in Paris. The delegates will have the opportunity to combine the best of science with this exceptional sports event. This will be a busy period, please book your travel in advance.
Novotel Paris Centre Eiffel Tower, 61 quai de Grenelle, Paris, France
A worldwide network assembling all cancer stakeholders to develop cutting edge concepts and clinical trials that improve survival for cancer patients.
WIN members include organizations representing all stakeholders in precision cancer medicine: cancer centers in 17 countries across 4 continents, major technology and pharmaceutical companies and institutes, patient advocacies, and health payers.
For information about WIN Consortium, its mission, vision, members and activities, please visit: www.winconsortium.org
Catherine Bresson, +33 1 45 59 58 43
Director of WIN Operational Team